A panel discussion led by renowned oncology Key Opinion Leaders on Checkpoint Inhibitors; an opportunity for learning and networking with oncology executives and research professionals.
Smith & Wollensky
Chicago's Premier Steakhouse
318 North State Street
Chicago, IL 60654
Friday, June 2, 2017
7:00pm - 9:00pm
What To Expect
A panel of seasoned clinicians and oncology executives from Midwest Melanoma Partnership and Accelovance discussing what's next in checkpoint inhibitors over cocktails and light fare.
CLINICAL TRIAL CONSIDERATIONS
Preparing for your next study involving checkpoint inhibitors
How checkpoint inhibitors are expanding into other oncology indications
Vice Chair & Associate Member, Department of Cutaneous Oncology,
Moffitt Cancer Center
Dr. Nikhil Khushalani is the Vice-Chair and an Associate Member in the department of Cutaneous Oncology at the Moffitt Cancer Center, Tampa. FL, and holds a joint appointment as Associate Professor in the Morsani College of Medicine, University of South Florida. Dr. Khushalani is a clinical investigator and his research centers around novel molecular therapeutics in melanoma and other skin cancers. Specifically, in examining the role of anti-angiogenic agents in melanoma as well as the pharmacoeconomic impact of the new agents we now have available in melanoma on our healthcare system.
Chair of Midwest Melanoma Partnership
Professor of Medicine and Oncology,
Svetomir N. Markovic, M.D., Ph.D. is the Chair of the Melanoma Disease Oriented Group of the Mayo Clinic Cancer Center, as well as the Chair of the Midwest Melanoma Partnership. Dr. Markovic is Professor of Medicine and Oncology in Rochester, NY where he holds a joint appointment in Oncology and Immunology and is an Associate Professor in the Department of Immunology. He is recognized with distinction as the Charles F. Mathy Professor in Melanoma Research. His research interests center on translational immunotherapeutics of cancer, focused on malignant melanoma and non-Hodgkin's lymphoma. This work includes development and clinical testing of cancer vaccines, immune-boosting agents, novel agents that reconstitute immunity in patients with cancer, and combination therapy directed at enhancing anti-tumor immune responses.
Dr. Dudek's expertise centers around the design and execution of clinical trials for cancer therapy with a special interest in the development of novel cancer therapeutics focused on targeted and signal transduction therapy of cancer. His background includes over 17 years of clinical cancer research experience, over 17 years in the clinical management of lung cancer, and over 12 years in the field of tumor angiogenesis, signal transduction, and cancer immunotherapy. Dr. Dudek chairs and manage a broad range of clinical trials (Phase I - III), from cooperative group, investigator-initiated, and industry sponsored studies) either therapeutic or non-therapeutic studies. He is a a member of the Respiratory Committee in Alliance & serves as co-chair of the Lung Cancer Program at UIC, and co-chair the Thoracic Clinical Trial Working Group at Big Ten Cancer Research Consortium.
Dr. Oliver has amassed significant clinical research experience in both preclinical and clinical experimentation in academia and the pharmaceutical industry. He has published several peer-reviewed articles in the areas of immunopharmacology and oncology and is a member of the American Society of Clinical Oncology. Dr. Oliver possesses strong therapeutic experience in the areas of oncology, hematology, vaccines, nutritional support, cytokines regulation, infectious disease, immunopharmacology, renal disease, and transplantation.
Dr. Dave has 25+ years of clinical research experience, including the conduct of over 100 studies with a focus on Hematology, Oncology and Transplantation as well as other areas of internal medicine. He possesses expertise in gene regulation, gene therapy and tumor immunology, clinical and academic expertise in hematology including coagulation disorders, oncology and transplantation, and industry experience in hematology/oncology drug development from pre-clinical to Phase IV, and in biosimilars/biobetters and immunotherapeutics.
Krystyna is a tenured clinical research executive with nearly 40 years’ experience in biopharma companies, top-tier CROs and SMOs. She has led, conducted or participated in over 100 clinical trials, with focus areas including Oncology and Rare Disease. Krystyna has extensive experience in patient recruitment, and overseen both regional and global teams in the successful execution of clinical research, and, in collaboration with her research teams, has achieved three approved compounds.